Skip to Content

Michael J Overman, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2000 Johns Hopkins School of Medicine, Baltimore, MD, MD, Medicine
1996 Brown University, Providence, RI, BS, Biochemistry
1995 Kings College, London, United Kingdom, Semester Abroad Program, English and Biology

Board Certifications

2007 Medical Oncology
2007 Hematology
2003 Internal Medicine


Academic Appointments

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007-8/2013
Clinical Specialist, David Geffen School of Medicine - UCLA, Los Angeles, CA, 6/2003-6/2004

Administrative Appointments/Responsibilities

Site Director of Hematology/Oncology for the University of Texas, Houston Internal Medicine Residency Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2008-present

Other Appointments/Responsibilities

Clinical Specialist, The University of Texas MD Anderson Cancer Center-Ambulatory Treatment and Emergency Care, Houston, TX, 9/2004-6/2007
Chief Resident, Harbor-UCLA, Los Angeles, CA, 6/2003-6/2004

Institutional Committee Activities

Member, Credentials Committee of the Medical Staff, MDACC, 9/2010-9/2013
Member, Staffing & Policy/Procedure Subcommittee, MDACC, 8/2010-2/2011
Member, Hematology/Oncology Fellowship Steering Committee, MDACC, 7/2009-present

Honors and Awards

2007 GI Symposium American Society of Clinical Oncology Merit Award Winner
2003-2004 Chief Resident Harbor UCLA Internal Medicine
1997 Johns Hopkins Deans Research Award

Selected Publications

Peer-Reviewed Original Research Articles

1. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 1/2010. e-Pub 11/2009. PMCID: PMC2813754.
2. Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, Ohinata A, Liu J, Wang X, Eng C. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer 116(2):316-22, 1/2010. e-Pub 11/2009. PMID: 19904805.
3. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 8/2009. PMID: 19470929.
4. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 27(16):2598-603, 6/2009. PMID: 19164203.
5. Overman MJ. Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res 3(3):90-6, 5/2009. PMCID: PMC2713134.
6. Blazer DG, Kishi Y, Maru D, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Nauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 26(33):5344-51, 11/20/2008. e-Pub 10/20/2008. PMID: 18936472.
7. Overman M, Kopetz S. Picking the right road for metastatic colorectal cancer patients. Oncology (Williston Park) 22(13):1482-3, 11/30/2008. PMID: 19227576.
8. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abburzzese J, Ajani J, Wolff Ra. Chemotherapy with 5-fluorouracil and a Platinum Compound Improves Outcomes in Metastatic Small Bowel Adenocarcinoma. Cancer 113(8):2038-2045, 10/2008. PMID: 18759326.
9. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445-54, 10/2008. e-Pub 6/5/2008. PMID: 18528634.
10. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9, 10/2008. PMID: 18798063.
11. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla E, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: A report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 9/2008. PMID: 18794067.
12. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol 26(12):2000-5, 4/2008. PMID: 18421052.
13. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19(3):553-9, 3/2008. e-Pub 12/2007. PMID: 18083690.
14. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer 7(1):55-9, 1/2008. PMID: 18279578.
15. Overman MJ, Hoff P. EGFR-targeted Therapies in Colorectal Cancer. Dis Colon Rectum 50(8):1-13, 8/2007. PMID: 17566832.
16. Overman M, Brass E. Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration. Thromb Haemost 92(4):886-7, 10/2004. PMID: 15499705.
17. David-Beabes GL, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM, Nelson WG. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol 17(6):1077-86, 12/2000. PMID: 11078791.
18. Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270(41):23895-8, 10/1995. PMID: 7592576.

Invited Articles

1. Cusack JC, Overman MJ, Wolff RA. Diagnosis and staging of small bowel neoplasms., 1/2009.
2. Cusack JC, Overman MJ, Wolff RA. Epidemiology, clinical features, and types of small bowel neoplasms., 1/2009.
3. Cusack JC, Overman MJ, Wolff RA. Treatment of small bowel neoplasms., 1/2009.


1. Lieu C, Lambert L, Wolff RA, Eng C, Lin E, Rafeeq S, Fournier K, Royal R, Mansfield P, Overman MJ. The role of surgical cytoreduction and systemic chemotherapy in metastatic poorly differentiated or signet ring cell adenocarcinomas of the appendix. GI ASCO. 2010 28 (#479), 1/2010.
2. Overman MJ, Hu C, Wolff RA, Chang GJ. Impact of lymph node evaluation on survival for small bowel adenocarcinoma: Analysis of the surveillance, epidemiology, and end results. ASCO 2009 Annual Meeting (#4596), 5/2009.
3. Shroff R, Javle M, Varadhachary G, Krishnan S, Crane C, Wen S, Abbruzzese J, Wolff R, Overman M,J. Improved relapse-free survival with the addition of systemic chemotherapy to adjuvant chemoradiation for high risk ampullary adenocarcinoma. GI ASCO 2009 (#250), 1/2009.
4. Kopetz S, Hoff PM, Eng C, Overman MJ, Glover KY, Chang DZ, Wolff RA, Abbruzzese JL, Ellis LM, Heymach JV. Levels of angiogenic cytokines prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab. GI ASCO 2009 (#292), 1/2009.
5. Kazmi SM, Phan, Jhamb J, Mani M, Tetzlaff E, Lin E, Ajani J, Abbruzzese JL, Overman MJ. Toxicity and efficacy of a weekly based docetaxel, cisplatin, and 5FU(DCF) as first-line treatment of advanced gastric and esophageal cancer. GI ASCO 2009 (#68), 1/2009.
6. Overman MJ, Varadachary G, Lin E, Morris J, Adinin R, Abbruzzese JL, Wolff RA. Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater. ASCO 2008 26 (#4538), 5/2008.

Grant & Contract Support

Title: A Phase 2 Proof of Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced Mestatic Panceratic Cancer (ACE-ST-003)
Funding Source: Acerta Pharmacueticals, inc
Role: Principal Investigator
Duration: 6/4/2015 - present
Title: A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite Instability High (MSI-H) Colon Cancer (CA209142)
Funding Source: Bristol-Myers Squibb, MDACC
Role: Principal Investigator
Duration: 4/2014 - present
Title: Small bowel cancer research
Funding Source: Kavanaugh Foundation
Role: Principal Investigator-MDACC
Duration: 1/1/2008 - 1/1/2012
Title: Retrospective analysis of weekly DCF chemotherapy for gastroesophageal carcinoma
Funding Source: Sanofi-Aventis
Role: Principal Investigator
Duration: 2007 - 2009

Last updated: 9/1/2015